NeoGenomics (NEO)

NeoGenomics Stock Price & Analysis


NEO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$6.85 - $54.74
Previous Close$8.94
Average Volume (3M)1.55M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$283.61M
Total Debt (Recent Filing)$217.08M
P/E Ratio-7.5
Next EarningsNov 01, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.19
Shares Outstanding125,795,904
Standard Deviation0.15
10 Day Avg. Volume1,186,355
30 Day Avg. Volume1,552,249
P/B Ratio12.46
P/S Ratio2.30
P/CF Ratio698.90
P/FCF Ratio-9.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside92.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $6.85 and its highest was $54.74 in the past 12 months.
    What is NeoGenomics’s market cap?
    Currently, no data Available
    When is NeoGenomics’s upcoming earnings report date?
    NeoGenomics’s upcoming earnings report date is Nov 01, 2022 which is in 37 days.
      How were NeoGenomics’s earnings last quarter?
      NeoGenomics released its earnings results on Aug 09, 2022. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.235 by $0.075.
        Is NeoGenomics overvalued?
        According to Wall Street analysts NeoGenomics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does NeoGenomics pay dividends?
          NeoGenomics does not currently pay dividends.
          What is NeoGenomics’s EPS estimate?
          NeoGenomics’s EPS estimate is -$0.21.
            How many shares outstanding does NeoGenomics have?
            NeoGenomics has 125,795,906 shares outstanding.
              What happened to NeoGenomics’s price movement after its last earnings report?
              NeoGenomics reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.235. Following the earnings report the stock price went up 14.174%.
                Which hedge fund is a major shareholder of NeoGenomics?
                Among the largest hedge funds holding NeoGenomics’s share is Royce & Associates LLC. It holds NeoGenomics’s shares valued at 5M.


                  NeoGenomics Stock Analysis

                  Smart ScoreNeutral
                  The NeoGenomics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

                  Similar Stocks
                  Price & Change
                  Thermo Fisher
                  IQVIA Holdings

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis